Skip to content

Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus

Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01760759
Enrollment
104
Registered
2013-01-04
Start date
2012-11-30
Completion date
2019-04-30
Last updated
2019-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

HIV, Antiretroviral therapy adherence

Brief summary

In this study, investigators propose to randomize 165 human immunodeficiency virus positive patients to one of three 16-week treatment conditions: (1) standard care; (2) standard care + cell phone-based adherence reminders; or (3) standard care + cell phone-based adherence reminders and contingency management. In this latter condition, patients will earn reinforcement for sending in time- and date-stamped self videos of antiretroviral therapy medication ingestion. Primary outcomes will include viral loads and self-report measures of adherence, and effects will be evaluated both during the treatment period and throughout a one-year follow-up. Investigators hypothesize that the cell phone reminder condition will improve adherence relative to standard care, and the cell phone reminder plus contingency management condition will have the best outcomes. Results from this study may have widespread implications for the use of cell phones as a novel technology to improve initial adherence to antiretroviral therapy, thereby reducing the spread of drug resistant human immunodeficiency virus strains to the community.

Interventions

BEHAVIORALcell phone reminders

Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.

Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
UConn Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \> 18 years * initiating or on an antiretroviral therapy regimen and have a viral load \>200 copies/mL in the past 6 months * one or more risk factors for poor adherence * English speaking * willing to use a cell phone to receive reminders and record medication ingestion for up to 16 weeks * able to read at 5th grade level and pass a brief quiz related to understanding the informed consent form

Exclusion criteria

* living in an environment or has a visiting nurse that dispenses antiretroviral therapy medication * participating in another antiretroviral therapy adherence study * uncontrolled psychiatric disorders * significant cognitive impairment

Design outcomes

Primary

MeasureTime frame
change in copies of human immunodeficiency virus per milliliterWeek 48
self-report of medication adherencebaseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026